InvestorsHub Logo

H2R

Followers 42
Posts 2160
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: None

Tuesday, 05/12/2020 1:44:54 PM

Tuesday, May 12, 2020 1:44:54 PM

Post# of 12137

We reported revenues of $9.8 million for the first quarter of 2020, an increase of 47% from the first quarter of 2019. This was primarily driven by record revenues from our commercial agreements supporting Gilead's YESCARTA and Novartis' KYMRIAH, which contributed $2.9 million in the first quarter of 2020, representing a 110% increase compared to the first quarter of 2019. In addition, bioservices revenue was $1.3 million and not included in last year's numbers.

We are pleased to report that in April, Gilead renewed its agreement with Cryoport, which covers Gilead's entire portfolio of therapies in development as well as YESCARTA for all -- for our temperature-controlled solutions.



Best of luck with your investments!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYRX News